Industry News

Some poorer nations hit by cuts in HIV/AIDS funding from rich donors have boosted their own spending in response, but not enough to make up for huge staff losses and drops in preventative drug use, UNAIDS said on Thursday. In its annual report for 2025, launched in South Africa, the agency also reiterated that if the Trump administration's cuts to the U.S. HIV programme remain permanent, there could be 6 million extra infections and 4 million more deaths by 2029. Trump's sudden slashing of finance for the President's Emergency Plan for AIDS Relief (PEPFAR) threw the global response to HIV/AIDS into disarray. Although many countries still have enough life-saving antiretroviral drugs, clinics aimed at vulnerable groups such as gay men, sex workers and teenage girls have shut due to a lack of paid staff, and prevention programmes have all but petered out. "Prevention was hit harder than treatment. Key populations were the worst affected ... they depended on tailored services by community leaders, and those were the first to go," UNAIDS Executive Director Winnie Byanyima told Reuters in an interview in Johannesburg. Byanyima said that even before the Trump cuts, donors were scaling back development assistance, notably European countries. "They've told us that it has...

Global Top 10 Cancer Drugs market to hit $198.8B by 2032 (10% CAGR). Fueled by rising cancer prevalence, aging population, and increased awareness. WILMINGTON, DE, UNITED STATES, July 11, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "Top 10 Cancer Drugs Market by Region (Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2018–2026." According to the report, the global top 10 cancer drugs industry generated $63.61 billion in 2018, and is estimated to reach $129.94 billion by 2026, witnessing a CAGR of 9.8% from 2019 to 2026. Cancer is caused when cells in the body grow excessively, leading to the formation of tumors. Cancer has different stages depending on its progress. Metastasis is the last stage of the disease, which is indicated by the invasion of the tumor into other parts of the body. The management of cancer patients requires the use of different types of drugs such as hormone therapy, immunotherapy, targeted therapy and others. Major market players covered in the report, such as - AbbVie Inc. Astellas Pharma Inc. AstraZeneca PLC Bristol-Myers Squibb Company Celgene Corporation F. Hoffmann-La Roche Ltd. Johnson & Johnson (Janssen Global Services, LLC) Merck & Co., Inc. Novartis AG Pfizer Inc. Key Benefits for Stakeholders - • The report provides quantitative analysis of market segments,...

Dr. Efatossadat Mirmoeini, Deputy of Food and Drug Affairs at Hamedan University of Medical Sciences, stated that no official licenses have been issued for online drug sales in Iran — and as a result, pharmacies in Hamedan Province are not permitted to offer such services. “Although there is a growing need for online pharmaceutical services across the country, proper infrastructure and full oversight by the Ministry of Health are essential prerequisites,” she explained. Until formal regulations and guidelines are officially issued, pharmacies are not allowed to collaborate with digital platforms. Once approved, Hamedan University of Medical Sciences will implement the policy according to national directives. At present, a pilot version of the program is being tested in select provinces for special patient groups, such as children with metabolic disorders, but it has not yet been rolled out nationwide.

The following Ordinary and Extraordinary General Meetings have been scheduled across several major pharmaceutical firms in Iran: 🟧 1) Aboureihan Pharmaceutical Company Ordinary General Meeting: June 7, 2025, at 10:00 AM Extraordinary General Meeting: June 7, 2025, at 11:00 AM Venue: Conference Hall, DarouPakhsh Pharmaceutical Manufacturing Company 🟧 2) Barkat Pharmaceutical Group (Extraordinary Meeting Only) Extraordinary General Meeting: June 16, 2025, at 11:00 AM Venue: Building No. 2, Industrial Management Complex, Valfajr Industrial Town 🟧 3) Razak Laboratories Ordinary General Meeting: June 16, 2025, at 10:00 AM Extraordinary General Meeting: June 16, 2025, at 11:00 AM Venue: Conference Hall, DarouPakhsh Pharmaceutical Manufacturing Company 🟧 4) Pars Darou Company Annual Ordinary General Meeting: June 17, 2025, at 10:00 AM Venue: Talash Hall (Valiasr Ave., before Parkway intersection) 🟧 5) Iranian Injectable and Pharmaceutical Products Company

IRNA Reports on the Complex Realities of Iran’s Pharmaceutical System In a recent in-depth report, IRNA News Agency shed light on the ongoing challenges within Iran’s pharmaceutical sector, especially concerning rare diseases and unlisted medications. A striking excerpt from the report reads: “The drug exists — but it’s not on the list!” This may be the most accurate way to describe the condition of patients with rare diseases, whose prescriptions often include medications that are not officially registered in Iran’s national pharmaceutical system. These so-called "single-prescription drugs" form a critical yet highly complicated link in the treatment chain. They are often prescribed to ensure survival or reduce severe pain — yet their journey to the patient is riddled with administrative, financial, and legal barriers.

Baratali Salehi, Judicial Deputy and Supervisory Official at the Isfahan Provincial Office of the Government Sanctions Organization (Ta'zirat-e Hokoomati), announced that daily inspections are being carried out across companies and pharmacies distributing infant formula and specialized medicines. Violations identified during these inspections include: Hoarding in warehouses Drip-feeding distribution by suppliers to unauthorized agents Unfair distribution to pharmacies against allocated quotas Storage in unauthorized locations Failure to register inventory in official tracking systems Reports of these violations have been submitted to the Ta’zirat office in Isfahan for legal processing. According to Clause 4, Article 18 of the Law on Combating Goods Smuggling, such offenses can lead to confiscation of seized goods, enforced redistribution through official channels, and substantial monetary penalties as disciplinary sanctions.